• Tue. Oct 26th, 2021

Modern vaccine, 100% efficacy in the 12-18 age group

Byeditorial

May 25, 2021

Moderna’s covid vaccine shows 100% effectiveness in 12-18 year olds. And in this age group, “no significant safety issues” are encountered. This is what the US pharmaceutical company announces by communicating that the phase 2/3 TeenCOVE study on its vaccine (mRNA-1273) for adolescents reaches the primary endpoint of immunogenicity not lower than that of the adult comparison group of the phase study 3. High protection data are found already after the first shield injection, reports Moderna. Using the case definition of the Center for Disease Control and Prevention (Cdc), a vaccine efficacy of 93% was observed after the first dose. After the two doses, no cases of Covid-19 were observed, using the primary case definition. And this result is consistent with a vaccine efficacy of 100%. The TeenCOVE study enrolled more than 3,700 participants between the ages of 12 and 18 in the United States. Moderna will present “at the beginning of June” the results of the phase 2/3 study on its anti-Covid vaccine in adolescents aged 12 to 18 “to the US FDA and other regulatory bodies globally, asking for the authorization” of the product approved today for the population over 18. This was stated by St├ęphane Bancel, CEO of the American pharmaceutical group. “We are encouraged by the fact that” the vaccine “mRna-1273 has been highly effective in preventing Covid-19 in adolescents – underlines the CEO – It is particularly exciting to see that the Moderna Covid-19 vaccine can prevent Sars-CoV-2 infection “, he adds, confirming the commitment” to do our part to help end the pandemic “.

One thought on “Modern vaccine, 100% efficacy in the 12-18 age group”
  1. editorial says:

    https://zenodo.org/record/4787785
    https://zenodo.org/record/4787833
    https://zenodo.org/record/4787809
    https://zenodo.org/record/4787757
    https://zenodo.org/record/4787845
    https://zenodo.org/record/4787839
    https://zenodo.org/record/4787803
    https://zenodo.org/record/4787725
    https://zenodo.org/record/4787813
    https://zenodo.org/record/4787843
    https://zenodo.org/record/4787807
    https://zenodo.org/record/4787841
    https://zenodo.org/record/4787783
    https://zenodo.org/record/4787861
    https://zenodo.org/record/4787920
    https://zenodo.org/record/4787932
    https://zenodo.org/record/4787968
    https://zenodo.org/record/4787898
    https://zenodo.org/record/4787878
    https://zenodo.org/record/4787930
    https://zenodo.org/record/4787946
    https://zenodo.org/record/4787896
    https://zenodo.org/record/4787918
    https://zenodo.org/record/4787952
    https://zenodo.org/record/4787964
    https://zenodo.org/record/4787906
    https://zenodo.org/record/4787888
    https://zenodo.org/record/4787944
    https://zenodo.org/record/4787910
    https://zenodo.org/record/4787882
    https://zenodo.org/record/4787902
    https://zenodo.org/record/4787938
    https://zenodo.org/record/4787873
    https://zenodo.org/record/4787904
    https://zenodo.org/record/4787894
    https://zenodo.org/record/4787958
    https://zenodo.org/record/4787924
    https://zenodo.org/record/4787950
    https://zenodo.org/record/4787960
    https://zenodo.org/record/4787940
    https://zenodo.org/record/4787914
    https://zenodo.org/record/4787928
    https://zenodo.org/record/4787891
    https://zenodo.org/record/4787908
    https://zenodo.org/record/4787892
    https://zenodo.org/record/4787876
    https://zenodo.org/record/4787916
    https://zenodo.org/record/4787970
    https://zenodo.org/record/4787884
    https://zenodo.org/record/4787954

Comments are closed.